We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?
Read MoreHide Full Article
We expect Johnson & Johnson (JNJ - Free Report) to beat expectations when it reports second-quarter 2022 results on Jul 19, before market open. In the last-reported quarter, the company delivered an earnings surprise of 2.69%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 5.41%, on average.
J&J’s stock has risen 2.7% this year so far compared with an increase of 4% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have outperformed the market this time around as well led by increased penetration and share gains of key products such as Darzalex and Stelara.
The Zacks Consensus Estimate for Darzalex and Stelara is pegged at $1.83 billion and $2.63 billion, respectively.
Other core products like Invega Sustenna and new drugs, Erleada and Tremfya might have contributed significantly to sales growth. However, lower sales of key medicines, Imbruvica and Xarelto, had hurt the top line in the first quarter. It is unlikely that sales of these drugs might have improved in the second quarter. The Zacks Consensus Estimate for Invega Sustenna and Tremfya is $1.06 billion and $665 million, respectively.
Rising competitive pressure in the United States to new oral competition is likely to have hurt the sales of key drug, Imbruvica in the second quarter. The Zacks Consensus Estimate for Imbruvica is $1.06 billion. The Zacks Consensus Estimate for Xarelto is $578 million.
The contribution of J&J’s single-dose COVID-19 vaccine is likely to have been minimum to sales growth in the second quarter due to demand uncertainty. Also in May, J&J updated the label of its COVID-19 vaccine to mention the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare syndrome characterized by blood clots and low platelet count. J&J’s decision to update its label came on the heels of the FDA’s announcement on May 5 to limit the authorized use of its vaccine due to the risk of TTS.
Generic/biosimilar competition for drugs like Zytiga, Procrit/Eprex and Remicade is likely to have hurt the top line.
The Zacks Consensus Estimate for J&J’s Pharmaceuticals unit is $13.24 billion.
With regard to the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued into the second. J&J saw a steady uptick in surgical procedures in the first quarter with the easing of COVID restrictions in several countries, a trend that is likely to have continued in the second quarter. This, coupled with better commercial execution and uptake from recently launched products, is likely to have boosted sales in the segment in the second quarter. The Zacks Consensus Estimate for J&J’s Medical Devices segment is $6.87 billion.
In the Consumer Healthcare segment, external supply constraints (due to raw material availability and labor shortages) and inflationary pressure are likely to have continued to hurt sales of the skin health and beauty franchise. The OTC segment is likely to have done well this time around as well.
The Zacks Consensus Estimate for J&J’s Consumer Healthcare segment is $3.70 billion.
J&J plans to separate its Consumer Health segment into a new publicly-traded company
Management might announce key executive leadership appointments for the new Consumer Health company on the second-quarter conference call and also the new company name and headquarter location.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +0.89% as the Most Accurate Estimate of $2.61 is higher than the Zacks Consensus Estimate of $2.59. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck’s stock has risen 22.5% this year so far. Merck topped earnings estimates in three of the last four quarters. Merk has a four-quarter earnings surprise of 13.42%, on average. MRK is scheduled to release its second-quarter 2022 results on Jul 28.
Biogen (BIIB - Free Report) has an Earnings ESP of +4.41% and a Zacks Rank #3.
Biogen’s stock has declined 10.7% this year so far. Biogen topped earnings estimates in three of the last four quarters and has a four-quarter earnings surprise of 5.86%, on average. BIIB is scheduled to release its second-quarter 2022 results on Jul 20.
BioNTech (BNTX - Free Report) has an Earnings ESP of +31.16% and a Zacks Rank #2.
BioNTech’s stock has plunged 40.1% in the past year. BioNTech topped earnings estimates in all the last four quarters. BioNTech has a four-quarter earnings surprise of 56.87%, on average.
Image: Bigstock
J&J (JNJ) to Begin Pharma Sector's Q2 Earnings With a Beat?
We expect Johnson & Johnson (JNJ - Free Report) to beat expectations when it reports second-quarter 2022 results on Jul 19, before market open. In the last-reported quarter, the company delivered an earnings surprise of 2.69%.
The healthcare bellwether’s performance has been pretty impressive, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 5.41%, on average.
Johnson & Johnson Price and EPS Surprise
Johnson & Johnson price-eps-surprise | Johnson & Johnson Quote
J&J’s stock has risen 2.7% this year so far compared with an increase of 4% for the industry.
Image Source: Zacks Investment Research
Factors to Consider
J&J’s Pharma segment is expected to have outperformed the market this time around as well led by increased penetration and share gains of key products such as Darzalex and Stelara.
The Zacks Consensus Estimate for Darzalex and Stelara is pegged at $1.83 billion and $2.63 billion, respectively.
Other core products like Invega Sustenna and new drugs, Erleada and Tremfya might have contributed significantly to sales growth. However, lower sales of key medicines, Imbruvica and Xarelto, had hurt the top line in the first quarter. It is unlikely that sales of these drugs might have improved in the second quarter. The Zacks Consensus Estimate for Invega Sustenna and Tremfya is $1.06 billion and $665 million, respectively.
Rising competitive pressure in the United States to new oral competition is likely to have hurt the sales of key drug, Imbruvica in the second quarter. The Zacks Consensus Estimate for Imbruvica is $1.06 billion. The Zacks Consensus Estimate for Xarelto is $578 million.
The contribution of J&J’s single-dose COVID-19 vaccine is likely to have been minimum to sales growth in the second quarter due to demand uncertainty. Also in May, J&J updated the label of its COVID-19 vaccine to mention the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare syndrome characterized by blood clots and low platelet count. J&J’s decision to update its label came on the heels of the FDA’s announcement on May 5 to limit the authorized use of its vaccine due to the risk of TTS.
Generic/biosimilar competition for drugs like Zytiga, Procrit/Eprex and Remicade is likely to have hurt the top line.
The Zacks Consensus Estimate for J&J’s Pharmaceuticals unit is $13.24 billion.
With regard to the MedTech segment, the recovery in demand trends seen in the first quarter is likely to have continued into the second. J&J saw a steady uptick in surgical procedures in the first quarter with the easing of COVID restrictions in several countries, a trend that is likely to have continued in the second quarter. This, coupled with better commercial execution and uptake from recently launched products, is likely to have boosted sales in the segment in the second quarter. The Zacks Consensus Estimate for J&J’s Medical Devices segment is $6.87 billion.
In the Consumer Healthcare segment, external supply constraints (due to raw material availability and labor shortages) and inflationary pressure are likely to have continued to hurt sales of the skin health and beauty franchise. The OTC segment is likely to have done well this time around as well.
The Zacks Consensus Estimate for J&J’s Consumer Healthcare segment is $3.70 billion.
J&J plans to separate its Consumer Health segment into a new publicly-traded company
Management might announce key executive leadership appointments for the new Consumer Health company on the second-quarter conference call and also the new company name and headquarter location.
Earnings Whispers
Our proven model predicts an earnings beat for J&J in the to-be-reported quarter. A stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for a likely positive surprise. This is the case here, as elaborated below.
Earnings ESP: J&J’s Earnings ESP is +0.89% as the Most Accurate Estimate of $2.61 is higher than the Zacks Consensus Estimate of $2.59. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: J&J has a Zacks Rank #3
Other Stocks to Consider
Here are some large drug stocks that also have the right combination of elements to beat on earnings this time around:
Merck (MRK - Free Report) has an Earnings ESP of +7.18% and a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.
Merck’s stock has risen 22.5% this year so far. Merck topped earnings estimates in three of the last four quarters. Merk has a four-quarter earnings surprise of 13.42%, on average. MRK is scheduled to release its second-quarter 2022 results on Jul 28.
Biogen (BIIB - Free Report) has an Earnings ESP of +4.41% and a Zacks Rank #3.
Biogen’s stock has declined 10.7% this year so far. Biogen topped earnings estimates in three of the last four quarters and has a four-quarter earnings surprise of 5.86%, on average. BIIB is scheduled to release its second-quarter 2022 results on Jul 20.
BioNTech (BNTX - Free Report) has an Earnings ESP of +31.16% and a Zacks Rank #2.
BioNTech’s stock has plunged 40.1% in the past year. BioNTech topped earnings estimates in all the last four quarters. BioNTech has a four-quarter earnings surprise of 56.87%, on average.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.